|250.15||+2.75||+1.11%||Vol 570.13K||1Y Perf -10.09%|
|May 26th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||326.00||Analyst Rating||Strong Buy 1.31|
|Potential %||30.32||Finscreener Ranking||★★★ 49.17|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 50.43|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 62.42|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★ 38.33|
|Price Range Ratio 52W %||21.30||Earnings Rating||Strong Buy|
|Market Cap||23.19B||Earnings Date||28th Apr 2022|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||5.88|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||817.14K|
|Avg. Monthly Volume||900.31K|
|Avg. Quarterly Volume||826.20K|
Laboratory Corporation of America Holdings (NYSE: LH) stock closed at 250.15 per share at the end of the most recent trading day (a 1.11% change compared to the prior day closing price) with a volume of 570.13K shares and market capitalization of 23.19B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 72400 people. Laboratory Corporation of America Holdings CEO is Adam H. Schechter.
The one-year performance of Laboratory Corporation of America Holdings stock is -10.09%, while year-to-date (YTD) performance is -20.39%. LH stock has a five-year performance of 78.55%. Its 52-week range is between 232.01 and 317.17, which gives LH stock a 52-week price range ratio of 21.30%
Laboratory Corporation of America Holdings currently has a PE ratio of 11.40, a price-to-book (PB) ratio of 2.15, a price-to-sale (PS) ratio of 1.46, a price to cashflow ratio of 10.40, a PEG ratio of 2.32, a ROA of 10.49%, a ROC of 13.52% and a ROE of 20.80%. The company’s profit margin is 13.28%, its EBITDA margin is 23.20%, and its revenue ttm is $15.86 Billion , which makes it $171.08 revenue per share.
Of the last four earnings reports from Laboratory Corporation of America Holdings, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $5.88 for the next earnings report. Laboratory Corporation of America Holdings’s next earnings report date is -.
The consensus rating of Wall Street analysts for Laboratory Corporation of America Holdings is Strong Buy (1.31), with a target price of $326, which is +30.32% compared to the current price. The earnings rating for Laboratory Corporation of America Holdings stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Laboratory Corporation of America Holdings has a dividend yield of 1.15% with a dividend per share of $2.88 and a payout ratio of -%.
Laboratory Corporation of America Holdings has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.97, ATR14 : 6.75, CCI20 : 91.42, Chaikin Money Flow : 0.07, MACD : -2.92, Money Flow Index : 62.93, ROC : 3.95, RSI : 49.09, STOCH (14,3) : 87.55, STOCH RSI : 1.00, UO : 51.83, Williams %R : -12.45), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Laboratory Corporation of America Holdings in the last 12-months were: Adam H. Schechter (Option Excercise at a value of $0), Amy B. Summy (Option Excercise at a value of $0), Amy B. Summy (Sold 249 shares of value $65 290 ), Brian J. Caveney (Option Excercise at a value of $0), D. Gary Gilliland (Option Excercise at a value of $0), D. Gary Gilliland (Sold 500 shares of value $151 128 ), Garheng Kong (Option Excercise at a value of $0), Glenn A. Eisenberg (Option Excercise at a value of $0), Jean-Luc Belingard (Option Excercise at a value of $0), Jeffrey A. Davis (Option Excercise at a value of $0), Judith C. Seltz (Option Excercise at a value of $0), Kathryn E. Wengel (Option Excercise at a value of $0), Kerrii B. Anderson (Option Excercise at a value of $0), Lance V. Berberian (Option Excercise at a value of $0), Mark Schroeder (Option Excercise at a value of $0), Mark Schroeder (Sold 2 928 shares of value $809 932 ), Paul Kirchgraber (Option Excercise at a value of $0), Peter J. Wilkinson (Option Excercise at a value of $0), Peter M. Neupert (Option Excercise at a value of $0), Richelle P. Parham (Option Excercise at a value of $0), Robert Sanders Williams (Option Excercise at a value of $0), Robert Sanders Williams (Sold 572 shares of value $156 145 ), Sandra D. van der Vaart (Option Excercise at a value of $763 740), Sandra D. van der Vaart (Sold 12 046 shares of value $3 377 606 )
Sun, 15 May 2022 16:35 GMT Analysts Top Healthcare Picks: Laboratory (LH), Medios AG (MEDOF)- TipRanks. All rights reserved.
Sat, 30 Apr 2022 12:10 GMT Analysts Offer Insights on Healthcare Companies: Laboratory (LH), Resmed (RMD) and Anthem (ANTM)- TipRanks. All rights reserved.
Mon, 25 Apr 2022 16:36 GMT Laboratory (LH) Received its Third Buy in a Row- TipRanks. All rights reserved.
Tue, 15 Feb 2022 14:56 GMT Laboratory (LH) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Fri, 11 Feb 2022 13:06 GMT Analysts Are Bullish on These Healthcare Stocks: Laboratory (LH), Marinus (MRNS)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.